Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have been set forth that allow a biosimilars companies' commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater diversity of commercialization build-out models. Monoclonal Antibodies constitute the single largest product type in the global Biosimilars market, demand for which is expected to account for over 50% in 2023 and estimated to be US$17.2 billion.
This world market compendium by the publisher analyzes the market for Biosimilars at high level by product type, therapeutic area, and geographic region. The market is studied for historical/current trends and future forecast in terms of value in US$ for 2019, 2023, and 2026.
Product Types
- Monoclonal Antibodies
- Erythropoietin
- G-CSF
- Insulin
- Others
Therapeutic Areas
- Oncology
- Autoimmune Disorders
- Blood Disorders
- Growth Hormone Deficiency
- Others
Geographic Regions
- Europe
- North America
- Asia-Pacific
- Rest of World
Table of Contents
1. MARKET SEGMENTATION- Product Types
- Therapeutic Areas
- Geographic Regions
- Market Demand by Geographic Region
- Market Demand by Product Type
- Market Demand by Therapeutic Area
- Europe
- European Market Demand by Geographic Region
- European Market Demand by Product Type
- European Market Demand by Therapeutic Area
- North America
- North American Market Demand by Geographic Region
- North American Market Demand by Product Type
- North American Market Demand by Therapeutic Area
- Asia-Pacific
- Asia-Pacific Market Demand by Geographic Region
- Asia-Pacific Market Demand by Product Type
- Asia-Pacific Market Demand by Therapeutic Area
- Rest of World
- Rest of World Market Demand by Geographic Region
- Rest of World Market Demand by Product Type
- Rest of World Market Demand by Therapeutic Area
- mAbs - All the Rage in Biosimilars' New Wave
- Patent Expirations of Major Biologics Leads Way for Biosimilars
- Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation
- Availability of Biosimilar May Affect Biologic Drug Pricing
- Asia-Pacific Witnessing a Boom of Biosimilars
- Table 1: Global Biosimilars Demand by Geographic Region
- Table 2: Global Biosimilars Demand by Product Type
- Table 3: Global Biosimilars Demand by Therapeutic Area
- Table 4: European Biosimilars Demand by Geographic Region
- Table 5: European Biosimilars Demand by Product Type
- Table 6: European Biosimilars Demand by Therapeutic Area
- Table 7: North American Biosimilars Demand by Geographic Region
- Table 8: North American Biosimilars Demand by Product Type
- Table 9: North American Biosimilars Demand by Therapeutic Area
- Table 10: Asia-Pacific Biosimilars Demand by Geographic Region
- Table 11: Asia-Pacific Biosimilars Demand by Product Type
- Table 12: Asia-Pacific Biosimilars Demand by Therapeutic Area
- Table 13: Rest of world Biosimilars Demand by Geographic Region
- Table 14: Rest of World Biosimilars Demand by Product Type
- Table 15: Rest of World Biosimilars Demand by Therapeutic Area
- Table 16: List of Leading Bioloigcs Containing mAbs, Year of Approval and Patent Expiry in Europe and the United States
- Table 17: Global Biosimilar Approvals Since 2006: mAbs Occupy Major Share
- Table 18: Biosimilars Pipeline by Company
Companies Mentioned
- Amgen, Inc.
- AXXO GmbH
- Biocad
- Biogen, Inc.
- Bioton S.A.
- C.H. Boehringer Sohn AG & Co., KG.
- Coherus Biosciences
- Creative Biomart, Inc.
- Dong-A Socio Group
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly And Company
- Genor Biopharma Co., Ltd.
- Hetero Drugs Limited
- Insud Pharma SL
- Intas Pharmaceuticals Ltd
- Kashiv Biosciences LLC
- LG Chem
- Lupin Limited
- Mabxience SA
- Mylan, Inc
- Nippon Kayaku Co., Ltd.
- Pfizer, Inc.
- Reliance Life Sciences Pvt., Ltd.
- Sandoz International GmbH
- Shanghai Henlius Biotech, Inc.
- Stada Arzneimittel AG
- Teva Pharmaceutical Industries Limited
- Wockhardt Limited
